Combination Therapy May Increase Lesion Closure in PCV - Takeaways - MDSpire

Combination Therapy May Increase Lesion Closure in PCV

The combination of photodynamic therapy and intravitreal  aflibercept did not improve 1-year visual acuity outcomes compared with aflibercept monotherapy.

  • By

  • Andrea Surnit

  • May 13, 2026

  • 3 min

Share

  • 1

    Combination therapy with reduced-fluence photodynamic therapy and aflibercept did not improve visual acuity compared to aflibercept alone.

  • 2

    The study showed higher early polypoidal lesion closure rates with combination therapy at week 12 compared to monotherapy.

  • 3

    At week 52, lesion closure rates were 73% for combination therapy versus 47% for monotherapy.

  • 4

    No serious adverse events were reported in either treatment group during the trial.

  • 5

    The study faced limitations due to a smaller sample size and delays, impacting the ability to draw definitive conclusions.

Original Source(s)

Combination Therapy May Increase Lesion Closure in PCV

  • by Andrea Surnit

  • May 13, 2026

Related Content

Racing Toward Efficient AI Workflows

At the Focus A-Eye Summit, in the session “Lessons from Formula One: Optimizing Clinical Workflow with AI,” experts examined how artificial intelligence can streamline and accelerate ophthalmic clinical workflows.

Diagnosing and Managing Polypoidal Choroidal Vasculopathy

Polypoidal choroidal vasculopathy (PCV) is a distinct choroidal vascular disorder often considered a variant of age-related macular degeneration (AMD), although features such as drusen, pigmentary changes, and geographic atrophy are uncommon.

New Product Applications: Introducing the Cirrus 6000

Discover how Zeiss's Cirrus 6000 OCT device revolutionizes eye care with faster analysis and enhanced capabilities for disease diagnosis and treatment.